Esperion Offers Results Of Five Studies Of Heart DrugPlymouth-based Esperion Therapeutics Monday announced the results from a Phase 1 study and four preclinical studies for its heart disease drug candidate ETC-1002. Initial results look promising.
Esperion Starts Phase 2 Trial Of Cholesterol Buster

More From CBS Detroit

Best Christmas Light Displays
Best Holiday Drink Ideas
Top Hidden Destinations

Watch & Listen